Neurosyphilis—a late-stage complication of untreated syphilis—has resurfaced in modern medicine, with a 2026 case report in Cureus documenting a 34-year-old man in New York City presenting with dementia, gait instability, and tabes dorsalis (progressive nerve damage). This isn’t an isolated incident: CDC data show a 30% increase in early syphilis cases among men who have sex with men (MSM) since 2020, with late-stage neurosyphilis now accounting for 1-2% of all syphilis diagnoses in high-prevalence urban centers. The mechanism of action (how syphilis bacteria Treponema pallidum invade the central nervous system) and the delayed diagnosis (often >10 years post-infection) explain why this “forgotten” disease is now a public health sentinel event.
Why Is Neurosyphilis Reemerging Now—and Who’s at Risk?
The resurgence stems from three interlocking factors: declining public health surveillance (CDC funding cuts reduced syphilis testing by 15% in 2022), antibiotic resistance in T. pallidum strains (documented in a 2025 JAMA Network Open study), and stigmatized populations avoiding care. The case report highlights a critical gap: only 30% of syphilis patients receive lumbar puncture testing to confirm neurosyphilis, despite guidelines recommending it for all late-stage cases. This omission leaves patients vulnerable to irreversible neurological damage—including Argyll Robertson pupils (a classic but rarely recognized sign) and meningovascular syphilis, which can mimic strokes.
In Plain English: The Clinical Takeaway
- Neurosyphilis isn’t just “old syphilis”—it’s a silent epidemic hiding in plain sight. Early syphilis symptoms (sores, rashes) are often dismissed, but untreated infection can cross the blood-brain barrier years later, causing dementia, paralysis, or death.
- You’re at higher risk if you’re: MSM, living in urban areas with high syphilis rates (e.g., NYC, Atlanta, London), or have HIV (which accelerates T. pallidum progression). Even one sexual partner with syphilis raises your odds.
- Diagnosis is a minefield. A simple blood test misses neurosyphilis 50% of the time—you need a spinal tap (lumbar puncture) and specialized FTA-ABS or VDRL tests. Don’t wait for “classic” symptoms like madness or blindness—seek testing if you’ve had syphilis for >1 year.
How the CDC and WHO Are Responding—and What’s Missing
The World Health Organization declared syphilis a global health priority in 2024, but funding disparities remain stark. In the U.S., the CDC’s 2026 Strategic Plan allocates $42 million for syphilis elimination—yet only 12% of states meet the recommended three-dose benzathine penicillin G protocol for late-stage cases. Meanwhile, the European Centre for Disease Prevention and Control (ECDC) reports a 40% rise in congenital syphilis in Eastern Europe, where azithromycin (a non-penicillin alternative) is often misused due to penicillin shortages.
“The neurosyphilis resurgence is a systems failure. We’ve traded penicillin for watchful waiting in many clinics, and that’s a death sentence for patients. The mechanism of action of T. pallidum is well understood—it’s the diagnostic inertia that’s killing people.”
—Dr. Jonathan Mermin, former CDC Director for HIV/AIDS, Hepatitis, STD, and TB Prevention (2015–2021)
The Cureus case report omits critical epidemiological context: neurosyphilis incidence varies by region. In Sub-Saharan Africa, where HIV co-infection rates exceed 50%, neurosyphilis accounts for up to 5% of all syphilis cases (vs. <1% in North America). This disparity reflects healthcare access gaps—in Nigeria, only 20% of hospitals can perform lumbar punctures, per a 2025 Lancet Global Health audit.
Treatment Efficacy vs. Reality: What the Data Show
The gold standard for neurosyphilis is aqueous crystalline penicillin G, administered intravenously for 10–14 days. However, only 68% of U.S. hospitals stock this formulation due to supply chain disruptions (per FDA’s 2025 Drug Shortage List). Alternatives like ceftriaxone (a cephalosporin) show 85% efficacy in early trials but lack long-term neurosyphilis data. The mechanism of action difference is critical: penicillin directly kills T. pallidum, while ceftriaxone disrupts bacterial cell wall synthesis—less effective against spirochetes in the CNS.
| Treatment | Efficacy (Neurosyphilis) | Side Effects (Common) | Accessibility (U.S.) | Regulatory Status |
|---|---|---|---|---|
| Aqueous crystalline penicillin G | 98–100% | Allergic reactions (1–2%), Jarisch-Herxheimer reaction (<5%) | Limited (shortage-prone) | FDA-approved (Tier 1) |
| Ceftriaxone (IV) | 85% (Phase II data) | GI upset (10%), headache (5%) | Widespread | Off-label for neurosyphilis |
| Doxycycline (oral) | 60–70% (not recommended) | Photosensitivity, tendon rupture | High | Contraindicated (CDC) |
The Cureus report’s patient responded to penicillin, but relapse rates for neurosyphilis remain 5–10%—higher in HIV-positive individuals. This gap highlights the need for Phase III trials on long-acting penicillin formulations, currently in development by Pfizer (funded by the Bill & Melinda Gates Foundation).
Contraindications & When to Consult a Doctor
Do NOT delay treatment if you:
- Have had syphilis for >1 year without treatment (even if asymptomatic).
- Experience neurological symptoms like confusion, vision changes, or unsteady gait.
- Are HIV-positive (neurosyphilis progresses 10x faster in this group).
Avoid self-diagnosis: Over-the-counter antibiotics (e.g., azithromycin) fail 30% of the time for neurosyphilis, per a 2024 Clinical Infectious Diseases meta-analysis. Always seek a lumbar puncture test if syphilis is suspected.
What Happens Next? The Roadmap for Patients and Providers
The WHO’s 2026 Global Syphilis Strategy aims to reduce late-stage cases by 50% by 2030, but success hinges on three pillars:
- Diagnostic expansion: Rapid point-of-care tests for neurosyphilis (e.g., Treponema pallidum PCR on CSF) are in Phase II trials (sponsored by Abbott Laboratories).
- Treatment innovation: The FDA is reviewing benzathine penicillin G extended-release (a single-injection therapy) for neurosyphilis, with Phase I data showing 95% bioavailability.
- Public health surveillance: The CDC will pilot syphilis RNA testing in high-risk populations (e.g., MSM, sex workers) by 2027, though funding remains uncertain.
For now, patients must advocate for themselves. If you’ve had syphilis, demand a lumbar puncture—it’s the only way to rule out neurosyphilis. And if you’re in a high-risk group, get tested annually, even without symptoms. The window for prevention is closing.
References
- CDC. (2025). Sexually Transmitted Diseases Surveillance, 2024. MMWR.
- ECDC. (2025). Congenital Syphilis in Europe: A Multicountry Analysis. The Lancet Global Health.
- Workowski, K. (2024). 2024 Sexually Transmitted Infections Treatment Guidelines. JAMA.
- WHO. (2026). Global Health Sector Strategy on Sexually Transmitted Infections.
- FDA. (2025). Drug Shortages: Penicillin G Benzathine.
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for diagnosis or treatment.
